Source comparison
Subcutaneous vs Nasal vs Oral: Delivery Method Trade-Offs
Subcutaneous injection achieves the highest mots-c bioavailability. Typically 95–98%. Because the peptide enters circulation through dermal capillaries without encountering enzymatic degradation barriers. The injection site doesn't significantly alter absorpti
This comparison does not assign a generated winner or score.
- Subcutaneous injection achieves the highest mots-c bioavailability. Typically 95–98%. Because the peptide enters circulation through dermal capillaries without encountering enzymatic degradation barriers. The injection site doesn't significantly alter absorption rate, though abdominal sites show slightly faster uptake due to higher regional blood flow. The primary trade-off is user compliance: subcutaneous protocols require sterile technique, needle handling, and consistent injection site rotation. For research contexts where precise dosing and maximal systemic exposure are critical, subcutaneous remains the reference standard.
- Nasal spray formulations trade some bioavailability (40–60%) for convenience and non-invasiveness. The mechanism relies on the nasal mucosa's pseudostratified columnar epithelium, which has tight junction permeability roughly 10× higher than intestinal epithelium. Mots C Nasal Spray formulations optimize absorption by combining the peptide with penetration enhancers. The variability comes from individual differences in nasal anatomy, mucus viscosity, and concurrent nasal congestion. Factors that don't affect subcutaneous delivery.
- Oral administration shows negligible mots-c bioavailability (under 5%) because gastric pH (1.5–3.5) and pepsin activity degrade the peptide within minutes. Even enteric-coated capsules that survive gastric transit face intestinal peptidases that cleave the chain before absorption. For practical research use, oral MOTS-c isn't viable.